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ABSTRACT
In response to endoplasmic reticulum (ER) stress, activation of pancreatic 
ER kinase (PERK) coordinates an adaptive program known as the integrated 
stress response (ISR) by phosphorylating translation initiation factor 2α (eIF2α). 
Phosphorylated eIF2α is quickly dephosphorylated by the protein phosphatase 1 and 
growth arrest and DNA damage 34 (GADD34) complex. Data indicate that the ISR can 
either promote or suppress tumor development. Our previous studies showed that the 
ISR is activated in medulloblastoma in both human patients and animal models, and 
that the decreased ISR via PERK heterozygous deficiency attenuates medulloblastoma 
formation in Patched1 heterozygous deficient (Ptch1+/−) mice by enhancing apoptosis 
of pre-malignant granule cell precursors (GCPs) during cell transformation. We showed 
here that GADD34 heterozygous mutation moderately enhanced the ISR and noticeably 
increased the incidence of medulloblastoma in adult Ptch1+/− mice. Surprisingly, 
GADD34 homozygous mutation strongly enhanced the ISR, but significantly decreased 
the incidence of medulloblastoma in adult Ptch1+/− mice. Intriguingly, GADD34 
homozygous mutation significantly enhanced pre-malignant GCP apoptosis in 
cerebellar hyperplastic lesions and reduced the lesion numbers in young Ptch1+/− 
mice. Nevertheless, neither GADD34 heterozygous mutation nor GADD34 homozygous 
mutation had a significant effect on medulloblastoma cells in adult Ptch1+/− mice. 
Collectively, these data imply the dual role of the ISR, promoting and inhibiting, in 
medulloblastoma tumorigenesis by regulating apoptosis of pre-malignant GCPs during 
the course of malignant transformation.
INTRODUCTION
Activation of pancreatic endoplasmic reticulum kinase 
(PERK), in response to endoplasmic reticulum (ER) stress, 
coordinates an adaptive program known as the integrated 
stress response (ISR, Figure 1) by phosphorylating the 
α subunit of the eukaryotic translation initiation factor 2 
(eIF2α) [1, 2, 3]. Phosphorylation of eIF2α inhibits global 
protein translation but stimulates the expression of certain 
stress-induced genes through induction of the transcription 
factor ATF4. On the other hand, phosphorylated eIF2α 
(p-eIF2α) is quickly dephosphorylated by the protein 
phosphatase 1 (PP1) and growth arrest and DNA damage 
34 (GADD34) complex [4, 5], allowing cells to recover 
from inhibition of global protein biosynthesis. Interestingly, 
induction of ATF4 by p-eIF2α stimulates the expression of 
the transcription factor CAATT enhancer binding protein 
homologous protein (CHOP), and results in upregulation of 
GADD34, which forms a tight autofeedback loop regulating 
activity of the ISR [6, 7, 8]. 
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Several lines of evidence have suggested that the 
PERK-mediated ISR plays an important role in tumor 
growth and invasion, including regulating tumor cell 
viability, tumor cell invasion, and angiogenesis [9, 10, 11]. 
Interestingly, recent studies showed that the ISR is also 
involved in the process of malignant transformation 
by regulating cell apoptosis [12, 13, 14]. However, the 
effects of the ISR on tumor development are controversial 
[15, 16, 17]. Some reports showed that the ISR attenuates 
cell apoptosis during malignant transformation and/or after 
malignant transformation, resulting in enhanced tumor 
development [10, 12]. In contrast, other reports showed 
that the ISR elevates cell apoptosis during malignant 
transformation and/or after malignant transformation, 
resulting in attenuated tumor development [13, 18].
Medulloblastoma can be classified into four major 
molecular subgroups based on the molecular profiling: 
sonic hedgehog (SHH) subgroup, WNT subgroup, 
subgroup 3, and subgroup 4 [19, 20]. Mice heterozygous 
for Patched1 (Ptch1+/−), a SHH receptor, are regarded 
as the best animal model to study the SHH subgroup 
of medulloblastoma [21, 22]. The development of 
medulloblastoma in Ptch1+/− mice exhibits distinct 
steps of progression [23, 24, 25]. These mice display 
hyperplastic lesions of pre-malignant granule cell 
precursors (GCPs) in the external granular layer (EGL) 
of the cerebellum starting at the age of 3 weeks, and the 
lesions persist as late as 6 weeks of age. While a few 
hyperplastic lesions undergo cell transformation and 
progress to malignancy, the majority of the lesions regress 
over time.
Recent studies showed that the PERK-mediated ISR 
participates in medulloblastoma development [23, 26, 27]. 
Activation of PERK signaling has been observed in 
pre-malignant GCPs in young Ptch1+/− mice and in 
medulloblastoma cells in human patients and animal 
models [27]. Importantly, our previous study showed 
that PERK haploinsufficiency reduces the incidence of 
medulloblastoma in Ptch1+/− mice. Intriguingly, PERK 
haploinsufficiency enhances apoptosis of pre-malignant 
GCPs in young Ptch1+/− mice, but has no significant 
effect on medulloblastoma cells in adult mice [27]. In 
this study, we sought to better understand the effects 
of the ISR on the development of medulloblastoma in 
Ptch1+/− mice by exploiting GADD34 mutant mice. We 
found that GADD34 heterozygous mutation noticeably 
increased the incidence of medulloblastoma in Ptch1+/− 
mice. Surprisingly, GADD34 homozygous mutation 
significantly decreased the incidence of medulloblastoma 
in Ptch1+/− mice, which was associated with enhanced 
apoptosis of pre-malignant GCPs in young mice. 
Additionally, GADD34 mutation, either heterozygous or 
homozygous, did not affect medulloblastoma cells in adult 
Ptch1+/− mice. Collectively, these data suggest a dual role 
of the ISR, promoting and inhibiting, in medulloblastoma 
tumorigenesis.
RESULTS
Dual role of the ISR in medulloblastoma 
formation in Ptch1+/− mice
Ptch1+/− mice develop symptomatic 
medulloblastoma typically between the ages of 2 and 8 
months [22, 27, 28]. Our previous study demonstrated 
activation of the PERK-mediated ISR in medulloblastoma 
cells in adult Ptch1+/− mice and in pre-malignant GCPs 
in young mice [27]. We also showed that GADD34 is 
upregulated in medulloblastoma in Ptch1+/− mice [27]. 
It is well documented that inhibition of GADD34, via 
either genetic or pharmacological approaches, elevates 
the ISR during ER stress [29, 30]. Gadd34 homozygous 
Figure 1: Schematic diagram of the PERK-mediated ISR. Under conditions of ER stress the PERK protein becomes activated 
by homodimerization and autophosphorylation (p-PERK).  p-PERK phosphorylates eIF2α, and results in inhibition of global protein 
translation and induction of cytoprotective genes by preferentially stimulating translation of ATF4.  ATF4 also enhances the expression 
of CHOP, which negatively regulates p-eIF2α level through induction of GADD34 that binds PP1 and dephosphorylates p-eIF2α. The 
moderate ISR promotes cell survival by modestly inhibiting protein translation and enhancing the expression of certain cytoprotective 
genes. In contrast, the strong ISR leads to cell apoptosis by strongly inhibiting protein translation and/or inducing CHOP expression.
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mutant (Gadd34−/−) mice appear healthy and do not 
display any abnormalities in the CNS under normal 
conditions [7, 26, 29]. Moreover, a report showed that 
Gadd34 heterozygous mutant (Gadd34+/−) mice are 
healthy and display evidence of haploinsufficiency 
[31]. To determine the effects of the enhanced ISR on 
medulloblastoma development, Ptch1+/− mice were 
crossed with Gadd34−/− mice, and then the resulting 
progeny were intercrossed to obtain Ptch1+/−; Gadd34 
wild type (Gadd34+/+) mice, Ptch1+/−; Gadd34+/− 
mice, and Ptch1+/−; Gadd34−/− mice. We monitored 
these mice daily up to 8 months to detect medulloblastoma 
phenotypes, including ataxia, decreased movement, poor 
grooming, and doming of the skull [21, 22]. We verified 
medulloblastoma formation in symptomatic mice by gross 
examination, namely determining enlargement of the skull 
and cerebellum, and by hematoxylin and eosin (H&E) 
staining. 
Our previous study showed that PERK heterozygous 
deficiency reduces the incidence of medulloblastoma in 
Ptch1+/− mice [27]. In agreement with this previous 
study, the frequency of symptomatic medulloblastoma in 
Ptch1+/−; Gadd34+/− mice was noticeably increased 
compared to Ptch1+/−; Gadd34+/+ mice (Figure 2A). 
We further performed necropsy on all 8-month-old 
asymptomatic mice. Gross examination and H&E staining 
revealed that 2 out of 55 asymptomatic Ptch1+/−; 
Gadd34+/+ mice and 6 out of 45 asymptomatic 
Ptch1+/−; Gadd34+/− mice developed medulloblastoma, 
respectively. Thus, GADD34 heterozygous mutation 
noticeably increased the incidence of medulloblastoma 
in Ptch1+/− mice (29 out of 68 Ptch1+/−; GADD34+/− 
mice vs 23 out of 76 Ptch1+/−; GADD34+/+ mice, 
Figure 2B). Western blot analysis showed that GADD34 
heterozygous mutation did not change p-eIF2α level, 
modestly elevated ATF4 level, and moderately increased 
CHOP level in medulloblastoma in Ptch1+/− mice 
(Figure 2C, 2D). It is known that elevation of p-eIF2α 
level in ER-stressed cells is transient and highly dynamic; 
however, elevation of CHOP level is relatively steady and 
long-lasting [8, 32]. The moderate elevation of CHOP level 
indicates moderately enhanced ISR in medulloblastoma 
in Ptch1+/−; Gadd34+/− mice compared to Ptch1+/−; 
Gadd34+/+ mice. Taken together, these results suggest 
GADD34 heterozygous mutation results in the noticeable 
increase of medulloblastoma incidence in Ptch1+/− mice 
by moderately enhancing the ISR.
Western blot analysis showed that GADD34 
homozygous mutation did not alter the level of p-eIF2α and 
moderately elevated the level of ATF4 in medulloblastoma 
in Ptch1+/− mice (Figure 2C). Importantly, the level of 
CHOP was strongly increased in medulloblastoma in 
Ptch1+/−; Gadd34−/− mice compared to Ptch1+/−; 
Gadd34+/+ mice (Figure 2C, 2D), suggesting that 
GADD34 homozygous mutation strongly elevates the ISR 
in medulloblastoma in Ptch1+/− mice. Surprisingly, the 
frequency of symptomatic medulloblastoma in Ptch1+/−; 
Gadd34−/− mice was significantly decreased compared 
to Ptch1+/−; Gadd34+/+ mice (Figure 2A). Moreover, 
gross examination and H&E staining revealed that 4 out of 
55 asymptomatic Ptch1+/−; Gadd34−/− mice developed 
medulloblastoma. Thus, GADD34 homozygous mutation 
significantly reduced the incidence of medulloblastoma in 
Ptch1+/− mice (9 out of 60 Ptch1+/−; Gadd34−/− mice 
vs 23 out of 76 Ptch1+/−; Gadd34+/+ mice, Figure 2B). 
Collectively, these results showed GADD34 homozygous 
mutation strongly enhances the ISR and results in the 
significant decrease of medulloblastoma incidence in 
Ptch1+/− mice.
GADD34 mutation did not affect cell 
proliferation, cell apoptosis, or angiogenesis in 
medulloblastoma in adult Ptch1+/− mice
Our previous study showed that the decreased 
ISR via PERK heterozygous deficiency has no effect 
on cell proliferation, cell apoptosis, or angiogenesis 
in medulloblastoma in adult Ptch1+/− mice [27]. 
We determined the effects of the enhanced ISR on 
medulloblastoma in adult Ptch1+/− mice. H&E staining 
showed that the morphology of medulloblastoma in both 
Ptch1+/−; Gadd34+/− mice and Ptch1+/−; Gadd34−/− 
mice was comparable with Ptch1+/−; Gadd34+/+ 
mice (Figure 3A–3C). Immunohistochemistry (IHC) for 
glial fibrillary acidic protein (GFAP) and synaptophysin 
showed that the expression pattern of both GFAP and 
synaptophysin in medulloblastoma in both Ptch1+/−; 
Gadd34+/− mice and Ptch1+/−; Gadd34−/− mice 
was comparable with Ptch1+/−; Gadd34+/+ mice 
(Figure 3D–3I). Western blot analysis showed the protein 
levels of GFAP and synaptophysin were comparable in 
medulloblastoma in these three groups of mice (Figure 3J). 
Bromodeoxyuridine (BrdU) labeling (Figure 4A–4C, 4M) 
and proliferating cell nuclear antigen (PCNA) IHC (data 
not shown) showed that GADD34 mutation, either 
heterozygous or homozygous, did not significantly affect 
the number of proliferating cells in medulloblastoma in 
Ptch1+/− mice. Moreover, terminal deoxynucleotidyl 
transferase-mediated biotinylated UTP nick end labeling 
(TUNEL) staining showed that GADD34 mutation, 
either heterozygous or homozygous, did not significantly 
alter cell apoptosis in medulloblastoma in Ptch1+/− 
mice (Figure 4D–4F, 4M). Several studies showed that 
the ISR stimulates angiogenesis in tumors, including 
medulloblastoma, by enhancing the expression of 
vascular endothelial growth factor A (VEGF-A) [26, 33]. 
However, VEGF-A IHC showed that GADD34 mutation, 
either heterozygous or homozygous, had no significant 
effect on VEGF-A expression in medulloblastoma in 
Ptch1+/− mice (Figure 4G–4I, 4M), and CD31 IHC 
showed that GADD34 mutation, either heterozygous or 
homozygous, did not significantly affect angiogenesis in 
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this tumor (Figure 4J–4L, 4N). Collectively, these data 
suggest that GADD34 mutation, either heterozygous or 
homozygous, has a minimal effect on cell proliferation, 
cell apoptosis, and angiogenesis in medulloblastoma in 
adult Ptch1+/− mice. Thus, it is unlikely that GADD34 
mutation influences medulloblastoma formation in 
Ptch1+/− mice through its effects on tumor cells.
GADD34 homozygous mutation increased pre-
malignant GCPs apoptosis in the cerebellum of 
young Ptch1 +/− mice
Medulloblastoma arises from GCPs in the cerebellar 
EGL of Ptch1+/− mice and exhibits distinct steps of 
progression [23, 24, 25]. GCPs proliferate, differentiate, 
migrate to the internal granule layer, and become mature 
granule neurons during early postnatal development. 
There are no GCPs in the EGL of normal mice at the 
age of 3 weeks [34]. Nevertheless, Ptch1+/− mice 
display hyperplastic lesions of pre-malignant GCPs in 
the cerebellar EGL starting at the age of 3 weeks, and 
the lesions persist as late as 6 weeks of age [23, 25, 35]. 
The majority of these hyperplastic lesions regress over 
time; however, a few hyperplastic lesions undergo cell 
transformation and progress to malignancy [25, 36]. Our 
previous study showed that the decreased ISR via PERK 
heterozygous deficiency enhances pre-malignant GCP 
apoptosis, resulting in the reduction of medulloblastoma 
incidence in Ptch1+/− mice [27]. We further determined 
the actions of the enhanced ISR in pre-malignant GCPs in 
young Ptch1+/− mice.
We serially sectioned whole paraffin-embedded 
half-cerebellum of 6-week-old mice, each half-cerebellum 
yielded ~ 210 5-µm-thick sections. Every tenth section in 
the series was either stained by H&E or immunostained by 
the NeuN antibody or PCNA antibody. The hyperplastic 
Figure 2: GADD34 mutation influenced medulloblastoma formation in Ptch1+/− mice. (A) The percentage of mice that 
developed symptomatic medulloblastoma by the age of 8 months. (B) The percentage of mice that developed medulloblastoma by the age 
of 8 months. Ptch1+/−; Gadd34+/+ mice, n = 76 animals; Ptch1+/−; Gadd34+/− mice, n = 68 animals; Ptch1+/−; Gadd34−/− mice, 
n = 60 animal. (C, D) Western blot analysis showed that GADD34 heterozygous mutation did not change p-eIF2α level, modestly elevated 
ATF4 level, and moderately increased CHOP level in the cerebellum of adult Ptch1+/− mice with medulloblastoma, and that GADD34 
homozygous mutation did not change p-eIF2α level, moderately elevated ATF4 level, and strongly increased CHOP level in the cerebellum 
of adult Ptch1+/− mice with medulloblastoma. 1, wild type mice; 2, Ptch1+/−; Gadd34+/+ mice; 3, Ptch1+/−; Gadd34+/− mice; 
4, Ptch1+/−; Gadd34−/− mice. N = 4 animals. Error bars represent SD, **P <0.01, *P <0.05.
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Figure 3: GADD34 mutation did not affect the morphology or differentiation of medulloblastoma in adult Ptch1+/− 
mice. (A, B, C) H&E staining showed that GADD34 mutation, either heterozygous or homozygous, did not change the morphology of 
medulloblastoma in adult Ptch1+/− mice. (D, E, F) GFAP IHC showed that GADD34 mutation, either heterozygous or homozygous, 
did not change the expression pattern of GFAP in medulloblastoma in adult Ptch1+/− mice. (G, H, I) Synaptophysin IHC showed that 
GADD34 mutation, either heterozygous or homozygous, did not change the expression pattern of synaptophysin in medulloblastoma 
in adult Ptch1+/− mice. (J) Western blot analysis showed that GADD34 mutation, either heterozygous or homozygous, did not change 
the protein level of GFAP or synaptophysin in the cerebellum of adult Ptch1+/− mice with medulloblastoma. 1, Ptch1+/−; Gadd34+/+ 
mice; 2, Ptch1+/−; Gadd34+/− mice; 3, Ptch1+/−; Gadd34−/− mice. N = 4 animals. Scale bars: A–C, 1000 µm; D–I, 50 µm.
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Figure 4: GADD34 mutation did not affect cell proliferation, cell apoptosis or angiogenesis in medulloblastoma in 
adult Ptch1+/− mice. (A, B, C, M) BrdU labeling revealed comparable number of proliferating cells in medulloblastoma in adult 
Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice, and Ptch1+/−; Gadd34−/− mice. (D, E, F, M) TUNEL staining revealed 
comparable number of apoptotic cells in medulloblastoma in adult Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice, and 
Ptch1+/−; Gadd34−/− mice. (G, H, I, M) VEGF-A IHC revealed comparable number of VEGF-A positive cells in medulloblastoma 
in adult Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice, and Ptch1+/−; Gadd34−/− mice. (J, K, L, N) CD31 IHC revealed 
comparable number of blood vessels in medulloblastoma in adult Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice, and 
Ptch1+/−; Gadd34−/− mice. N = 4 animals. Error bars represent SD. Scale bars: (A–I), 50 µm; (J–L), 100 µm. 
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lesions (Figure 5A–5C), which contained greater than 
10 pre-malignant GCPs that were negative for NeuN 
(a marker of mature neurons) and positive for PCNA were 
counted as described in our previous paper [27]. We found 
that the number of hyperplastic lesions in the cerebellum 
of 6-week-old Ptch1+/−; Gadd34+/− mice was slightly 
increased as compared to Ptch1+/−; Gadd34+/+ mice 
(Figure 5D). Interestingly, the number of hyperplastic 
lesions in the cerebellum of 6-week-old Ptch1+/−; 
Gadd34−/− mice was significantly reduced as compared 
to Ptch1+/−; Gadd34+/+ mice (Figure 5D).
ATF4 IHC showed that immunoreactivity of ATF4 
was noticeably increased in hyperplastic lesions in 
6-week-old Ptch1+/−; Gadd34+/− mice as compared to 
Ptch1+/−; Gadd34+/+ mice (Figure 5E, 5F), and that the 
level of ATF4 was further increased in hyperplastic lesions 
in Ptch1+/−; Gadd34−/−mice (Figure 5G). BrdU labeling 
(Figure 6A–6C, 6G) showed that GADD34 mutation, 
either heterozygous or homozygous, did not significantly 
alter the rate of cell proliferation in hyperplastic lesions 
in 6-week-old Ptch1+/− mice. Importantly, TUNEL 
labeling showed that GADD34 homozygous mutation 
significantly increased the number of apoptotic cells 
in hyperplastic lesions in 6-week-old Ptch1+/− mice 
(Figure 6D, 6F, 6H). Nevertheless, GADD34 heterozygous 
mutation did not significantly change the number of 
apoptotic cells in hyperplastic lesions in 6-week-old 
Ptch1+/− mice (Figure 6D, 6E, 6H). Taken together, 
our data suggest that the strongly enhanced ISR via 
GADD34 homozygous mutation significantly promotes 
pre-malignant GCP apoptosis and reduces the number of 
hyperplastic lesions in young Ptch1+/− mice, resulting in 
the significantly decreased incidence of medulloblastoma 
in adult Ptch1+/− mice. Nevertheless, the moderately 
enhanced ISR via GADD34 heterozygous mutation 
slightly increases the number of hyperplastic lesions in 
young Ptch1+/− mice and leads to the noticeably elevated 
incidence of medulloblastoma in adult Ptch1+/− mice.
DISCUSSION
Evidence is emerging that the PERK-mediated 
ISR can either promote or suppress tumorigenesis by 
regulating cell apoptosis during the course of malignant 
transformation [12, 13, 14, 17]. Using PERK heterozygous 
deficient mice, our previous study showed that the 
decreased ISR reduces the incidence of medulloblastoma 
in Ptch1+/− mice by enhancing pre-malignant GCP 
apoptosis during cell transformation [27]. In accordance 
with this previous study, we showed here that the 
moderately enhanced ISR via GADD34 heterozygous 
mutation slightly increased the number of hyperplastic 
lesions in young Ptch1+/− mice and noticeably increased 
the incidence of medulloblastoma in Ptch1+/− mice. 
Nevertheless, we also found that the strongly enhanced 
ISR via GADD34 homozygous mutation significantly 
increased pre-malignant GCP apoptosis in hyperplastic 
lesions and reduced the lesion numbers in young 
Ptch1+/− mice, resulting in the significant reduction 
of medulloblastoma incidence in adult Ptch1+/− mice. 
Interestingly, neither GADD34 heterozygous mutation 
nor GADD34 homozygous mutation had an effect on 
medulloblastoma cells in adult Ptch1+/− mice. Taken 
together, these findings suggest the dual role of the ISR 
in medulloblastoma tumorigenesis. Moderate activation of 
the ISR promotes medulloblastoma formation, but strong 
activation of the ISR suppresses the tumor formation.
Apoptosis functions as a natural barrier to 
malignant transformation [37, 38]. During the course 
of cell transformation, apoptosis triggered by cellular 
stresses counters unrestrained cell proliferation driven by 
mutation of oncogenes. ER stress is one of the cellular 
stresses that are activated in cells during malignant 
transformation. Recent studies showed that PERK 
activation in response to ER stress either promotes cell 
transformation by decreasing apoptosis or suppresses the 
transformation by increasing apoptosis [12, 13, 14, 17]. A 
number of studies showed that the effects of the PERK-
mediated ISR, beneficial or detrimental, on cells are 
activity-dependent [18, 39, 40, 41, 42]. The moderate ISR 
is beneficial to cells, but the strong ISR is detrimental 
to cells. Interestingly, our previous and current results 
indicate that the impact of the ISR on GCP apoptosis 
during cell transformation is also activity-dependent. 
Our previous paper showed that the decreased ISR via 
PERK heterozygous mutation enhances GCP apoptosis 
in hyperplastic lesions in young Ptch1+/− mice [27]. 
Herein, we showed that the strongly increased ISR via 
GADD34 homozygous mutation increased GCP apoptosis 
in hyperplastic lesions in young Ptch1+/− mice. Taken 
together, these data raise the possibility that the effects 
of the ISR, promoting or inhibiting, on tumorigenesis 
are determined by the activity of this pathway. Moderate 
activation of the ISR promotes cell transformation by 
suppressing apoptosis; however, strong activation of the 
ISR attenuates the transformation by facilitating apoptosis.
It was thought that strong activation of the ISR 
induces cell apoptosis through strong inhibition of 
protein biosynthesis and/or induction of CHOP [39, 43]. 
However, recent studies showed that CHOP induction is 
not necessary to lead to cell apoptosis [42, 44, 45].  We 
showed here that GADD34 homozygous mutation strongly 
increased the expression of CHOP in medulloblastoma but 
did not affect tumor cell apoptosis in adult Ptch1+/− mice. 
Moreover, we found that GADD34 homozygous mutation 
strongly enhanced the expression of ATF4 and increased 
pre-malignant GCP apoptosis in hyperplastic lesions in 
young Ptch1+/− mice. Nevertheless, IHC analysis showed 
that the immunoreactivity of CHOP was barely detectable 
in hyperplastic lesions in either young Ptch1+/−; 
Gadd34+/+ mice or Ptch1+/−; Gadd34−/− mice (data 
not shown). Clearly, there is no co-relationship between 
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strong CHOP induction and cell apoptosis in either 
hyperplastic lesions in young Ptch1+/−; Gadd34−/− mice 
or medulloblastoma in adult mice. These data rule out the 
possibility that CHOP is a major player in regulating cell 
apoptosis during the development of medulloblastoma 
in Ptch1+/−; Gadd34−/− mice. Therefore, it is possible 
that the strongly increased ISR induces GCP apoptosis 
in hyperplastic lesions in young Ptch1+/−; Gadd34−/− 
mice through strong inhibition of protein biosynthesis. 
Nevertheless, the molecular mechanisms by which 
the strongly increased ISR had no significant effect on 
medulloblastoma cells in adult Ptch1+/−; Gadd34−/− 
mice are unknown and merit further investigation. 
While we found that the incidence of 
medulloblastoma in Ptch1+/−; Gadd34+/− mice 
was noticeably increased as compared to Ptch1+/−; 
Gadd34+/+ mice (42.6% vs 30.3%, Figure 2B), the 
increase was not statistically significant. The conventional 
wisdom is that the value of the statistically non-significant 
data is in doubt. In this study, we used a large number of 
mice, around 70 mice per group. Moreover, the degree of 
increase (42.6%, Ptch1+/−; Gadd34+/− mice vs 30.3%, 
Ptch1+/−; Gadd34+/+ mice) was quite impressive. 
It is likely that the low incidence of medulloblastoma in 
Ptch1+/− mice (30.3%) is responsible for the statistically 
non-significant result. Therefore, we believed that it was 
necessary to include these important data in this report. 
Although the number of hyperplastic lesions in young 
Ptch1+/−; Gadd34+/− mice was slightly increased 
as compared to Ptch1+/−; Gadd34+/+ mice, we did 
not find evidence showing that GADD34 heterozygous 
mutation influenced pre-malignant GCP proliferation 
or apoptosis in the lesions. The mechanisms by which 
GADD34 heterozygous mutation noticeably enhances 
medulloblastoma tumorigenesis remain unknown. 
Clearly, the effects of GADD34 heterozygous mutation 
on medulloblastoma tumorigenesis warrant further 
investigation. A mouse model with a high incidence of 
medulloblastoma could be an ideal model to address this 
open question.
It has been shown that activation of the ISR in 
response to ER stress, which is induced by hypoxia and 
nutritional deficiency in the solid tumor microenvironment, 
plays a role in tumor development by regulating tumor 
cell viability, tumor invasion, and angiogenesis [9, 10, 11]. 
A report showed that GADD34 homozygous mutation 
Figure 5: GADD34 mutation altered the number of cerebellar hyperplastic lesions in young Ptch1+/− mice. (A, B, C) 
H&E staining revealed a hyperplastic lesion (arrows) in the cerebellum of 6-week-old Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− 
mice, and Ptch1+/−; Gadd34−/− mice. (D) The scatter plot showed that GADD34 heterozygous mutation slightly increased the number 
of hyperplastic lesions in the cerebellum of 6-week-old Ptch1+/− mice, and that GADD34 homozygous mutation significantly reduced the 
number of hyperplastic lesions in these mice. (E, F, G) ATF4 IHC showed that the level of ATF4 was moderately increased in hyperplastic 
lesions in the cerebellum of 6-week-old Ptch1+/−; Gadd34+/− mice and strongly increased Ptch1+/−; Gadd34−/− mice, compared to 
Ptch1+/−; Gadd34+/+ mice. N = 10 animals. Error bars represent SD, **P <0.01. Scale bars: (A–C), 200 µm; (E–G) 50 µm.
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enhances the ISR, increases VEGF-A expression and 
angiogenesis, and facilitates medulloblastoma development 
in mice that ectopically express the immune cytokine 
interferon-γ in the CNS during development [26]. Several 
studies also reported that the ISR stimulated the expression 
of VEGF-A in human medulloblastoma cells [46, 47]. 
Nevertheless, our previous study showed that PERK 
heterozygous deficiency does not influence cell proliferation 
or apoptosis, angiogenesis, or VEGF-A expression 
in medulloblastoma in adult Ptch1+/− mice [27]. In 
accordance with this previous study, we showed herein that 
GADD34 mutation, either heterozygous or homozygous, did 
not alter cell proliferation, cell apoptosis, angiogenesis, or 
VEGF-A expression in medulloblastoma in adult Ptch1+/− 
mice. Collectively, these data suggest that the effects of the 
ISR on tumor cells are cell-context dependent, possibly 
determined by genetic mutations and/or epigenetic changes 
in individual molecular subtypes of tumors. 
We showed that GADD34 mutation, either 
heterozygous or homozygous, elevated the level of 
CHOP but did not change the level of p-eIF2α in 
medulloblastoma in adult Ptch1+/− mice. The elevation 
of p-eIF2α level is transient and highly dynamic in ER-
stressed cells. Moreover, there is a lot of feedback in the 
ISR. The steady state levels of any ISR markers reflect the 
composite effect of the primary defect (such as GADD34 
mutation) and the feedback response, which may over-
shoot [8, 32]. Therefore, it is not surprising that we found 
the lack of effect of the GADD34 mutation on steady state 
levels of p-eIF2α in medulloblastoma in Ptch1+/− mice.
Figure 6: GADD34 homozygous mutation enhanced apoptosis of pre-malignant GCPs in hyperplastic lesions in the 
cerebellum of young Ptch1+/− mice. (A, B, C, G) BrdU labeling revealed comparable number of proliferating cells in hyperplastic 
lesions in the cerebellum of 6-week-old Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice, and Ptch1+/−; Gadd34−/− mice. 
(D, E, F, H) TUNEL staining revealed significantly increased number of apoptotic cells in diffuse hyperplastic lesions in 6-week-old 
Ptch1+/−; Gadd34−/− mice compared to Ptch1+/−; Gadd34+/+ mice. However, GADD34 heterozygous mutation did not alter the 
number of apoptotic pre-malignant GCPs in hyperplastic lesions in Ptch1+/− mice. N = 4 animals. Error bars represent SD, **P < 0.01. 
Scale bars: (A–B), 50 µm.
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In summary, using GADD34 mutant mice, the results 
presented in this study advance our understanding of the 
effects on the PERK-mediated ISR on medulloblastoma 
development. Moderate increase of the ISR via GADD34 
heterozygous mutation increased the incidence of 
medulloblastoma in Ptch1+/− mice. Nevertheless, strong 
increase of the ISR via GADD34 homozygous mutation 
decreased the incidence of medulloblastoma in Ptch1+/− 
mice by enhancing pre-malignant GCPs apoptosis during 
the course of cell transformation. This work represents the 
first in vivo experimental demonstration of the dual role of 
the ISR on tumorigenesis.
MATERIALS AND METHODS
Generation of mice
Ptch1+/− mice [21] on a mixed C57BL/6 x 129Sv 
background were purchased from Jackson laboratory 
(Bar Harbor, Maine). Ptch1+/− mice were crossed with 
Gadd34−/− mice on the C57BL/6 background [7, 26], 
and then the resulting progeny were intercrossed to obtain 
Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− mice 
as well as Ptch1+/−; Gadd34−/− mice. Genotypes were 
determined by PCR from DNA extracted from tail tips 
as described in previous papers [26, 27, 29]. Mice were 
monitored daily to detect medulloblastoma phenotypes, 
including ataxia, decreased movement, poor grooming, 
and doming of the skull, until the age of 8 months. All 
animal procedures were conducted in complete compliance 
with the NIH Guide for the Care and Use of Laboratory 
Animals and were approved by the Institutional Animal 
Care and Use Committee of the University of Minnesota.
Histology, IHC, and TUNEL staining
Adult mice with medulloblastoma phenotypes 
and all 8-month-old asymptomatic mice received an 
intraperitoneal injection of 100 mg/kg BrdU (Sigma-
Aldrich, St. Louis, MO) 2 h prior to perfusion. Six-week-
old asymptomatic mice received a BrdU injection 8 h prior 
to perfusion. Anesthetized mice were perfused through the 
left cardiac ventricle with 4% paraformaldehyde in 0.1 M 
phosphate buffer. Brains were bisected in the sagittal 
plane, and one-half was postfixed for at least 48 h in 4% 
paraformaldehyde in PBS, dehydrated through graded 
alcohols, and embedded in paraffin.  Serial sections of 
5 µm thickness were cut and every tenth section in the 
series was routinely stained with H&E. The other half of 
the brain was postfixed for 1 h in 4% paraformaldehyde in 
PBS, cryopreserved in 30% sucrose for 48 h, embedded 
in OCT compound, and frozen on dry ice. Frozen sections 
were cut in a cryostat at 10 µm thickness. IHC for NeuN 
(1: 200, Millipore, Temecula, CA), PCNA (1:50,000, 
Sigma-Aldrich), GFAP (1:1000, Covance, Princeton, 
NJ), synaptophysin (1:200, Millipore), VEGF-A (1:50, 
Santa Cruz Biotechnology, Dallas, TX), and ATF4 (1:100, 
Abcam, Cambridge, MA) were performed on paraffin 
sections. IHC for CD31 (1:50, Santa Cruz Biotechnology) 
was performed on cryosections. All primary antibodies 
were detected using the Vectastain ABC kits (Vector 





 reagent (Vector Laboratories) as substrate.
TUNEL staining was performed on paraffin 
sections using the ApopTag kit (Millipore) according to 
the manufacturer’s instructions. IHC for BrdU (1:1000; 
Sigma-Aldrich), was performed on paraffin sections as 
described in our previous papers. We quantified positive 
cells for BrdU, TUNEL and VEGF-A as well as CD31 
positive blood vessels in the center of medulloblastoma or 
hyperplastic lesions in the cerebellum as described in our 
previous papers [26, 27, 48].
Western blot analysis
Cerebellar tissues were removed from adult 
control wild type mice as well as adult symptomatic 
Ptch1+/−; Gadd34+/+ mice, Ptch1+/−; Gadd34+/− 
mice, and Ptch1+/−; Gadd34 −/− mice, which displayed 
typical medulloblastoma clinical phenotypes and 
enlarged cerebellum. These tissues were homogenized 
in 5 volumes of Triton X-100 buffer using a motorized 
homogenizer as previously described [27, 49]. After 
incubation on ice for 15 min, the extracts were cleared 
by centrifugation at 14,000 rpm for 30 min twice. The 
protein concentration of each extract was determined by 
DC Protein Assay (Bio-Rad Laboratories, Hercules, CA). 
The extracts (120 µg) were separated by SDS-PAGE 
and transferred to nitrocellulose membranes. The blots 
were then incubated with primary antibodies to p-eIF2α 
(1:1000, Cell Signaling Technology, Danvers, MA), eIF2α 
(1:1000, Santa Cruz Biotechnology), ATF4 (1:1000, 
Abcam), CHOP (1:1000, Thermo Scientific, Grand 
Island, NY), GFAP (1:1000, Covance), synaptophysin 
(1:1000, Millipore), and actin (1:5000, Sigma-Aldrich), 
followed by the HRP-conjugated secondary antibody 
(Vector Laboratories). The chemiluminescent signal was 
detected by the ECL Detection Reagents (GE Healthcare 
Biosciences, Piscataway, NJ). The intensity of the 
recorded chemiluminescence signal was quantified using 
the ImageQuantTL software from GE Healthcare Life 
Sciences.
Statistical methods 
Data were expressed as mean ± standard deviation 
(SD). Comparisons between multiple groups were 
statistically evaluated by the one-way ANOVA test using 
Prism 6 (GraphPad, Software Inc., La Jolla, CA). The 
incidence of symptomatic medulloblastoma between 
Ptch1+/−; Gadd34+/+ mice and Ptch1+/−; Gadd34+/− 
mice as well as between Ptch1+/−; Gadd34+/+ mice and 
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Ptch1+/−; Gadd34−/− mice was statistically evaluated 
by Kaplan-Meier analysis and the incidence of total 
medulloblastoma between two groups was statistically 
evaluated by χ2 test using Prism 6 (GraphPad). P < 0.05 
was considered significant.
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